scholarly journals Efficacy and Safety of Thrombectomy Combined with Intracoronary Administration of Tirofiban in ST-segment Elevation Myocardial Infarction (STEMI)

2016 ◽  
Vol 22 ◽  
pp. 2699-2705 ◽  
Author(s):  
Lu Gao ◽  
Zhenhua Cao ◽  
Hong Zhang
Keyword(s):  
Myocardial Infarction ◽  
Efficacy And Safety ◽  
St Segment Elevation ◽  
Segment Elevation Myocardial Infarction ◽  
Intracoronary Administration ◽  
St Segment

scholarly journals Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic

2020 ◽  
Vol 48 (10) ◽  
pp. 030006052096615
Author(s):  
Nan Wang ◽  
Min Zhang ◽  
Huajun Su ◽  
Zhonglue Huang ◽  
Yongbo Lin ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Coronary Intervention ◽  
Efficacy And Safety ◽  
St Segment Elevation ◽  
Segment Elevation Myocardial Infarction ◽  
Reasonable Alternative ◽  
St Segment ◽  
Wire Crossing ◽  
Percutaneous Coronary ◽  
Reperfusion Strategy

Objective No data are available to develop uniform recommendations for reperfusion therapies in ST-segment elevation myocardial infarction (STEMI) during the coronavirus disease 2019 (COVID-19) pandemic. We aimed to fill the evidence gap regarding STEMI reperfusion strategy during the COVID-19 era. Methods Clinical characteristics and outcomes for 17 patients with STEMI who received fibrinolysis during the COVID-19 pandemic were compared with 20 patients who received primary percutaneous coronary intervention (PPCI), and were further compared with another 41 patients who received PPCI in the pre-COVID-19 period. Results In patients with STEMI, fibrinolysis achieved a comparable in-hospital and 30-day primary composite end point, as compared with those who received PPCI during the COVID-19 pandemic. No major bleeding was detected in either group. Compared patients with STEMI who received PPCI in the pre-COVID-19 period, we found a remarkable extension of chest pain onset-to-first medical contact (FMC) and FMC-to-wire crossing times, significantly increased number and length of stents, and much worse thrombolysis in myocardial infarction flow in patients with STEMI who received PPCI during the COVID-19 pandemic. Conclusion Owing to its considerable efficacy and safety and advantages in conserving medical resources, we recommend fibrinolysis as a reasonable alternative for STEMI care during the COVID-19 pandemic.

Sign in / Sign up

Export Citation Format

Share Document